Extavia vs Betaseron

I have had a letter today to say that I am being switched from Betaseron to Extavia, the letter says the drug is identical. I trust you guys much more than our NHS. Is it identical?

I have been on Betaseron for 2 years with no side effects and am happy with it. Obviously with the NHS I have no choice about the change.

Any insight  would be greatly appreciated.

Mand

[steph74]

I don't know anything about it, but I looked it up and it looks like it's just betaseron sold under a branded version from novartis.  sorry i can't be more help.

[Mand125]

Thank you Steph for taking the trouble to look it up for me, I did try googling it but wasn't really getting anywhere.

Mand

[steph74]

Try this link:  http://www.novartis.com/newsroom/media-releases/en/2009/1335044.shtml  (It's from the manufacturer.)

[sllowe]

Mand,

Nice to see you. I've only heard here on the forum that it's the same. Wonder why they'd switch, if it's indeed an exact match. And, you side affectless!

Steph74, if you have time, would you mind to post the guts, or summary of the press release here on this thread? It'd be a nice go-to for us in the future....

-shell

[Mand125]

step74 - Thank you for the link Steph, I will go check it out.

sllowe - Hi Ess, I can only guess the switch is a financial thing and that the NHS are getting the Extavia cheaper than Betafetron (am I being cynical?)

I suppose I just got used to things, the autoinjector will change, the delivery company will change and yes it has all been going so well.

I will let the forum know how it goes though I think it will be a couple of months till I start. - I have to go see the nurse in 3 weeks to be taught how to use the new autoinjector.

Thanks for your replies

Mand

[steph74]

Here's the press release:

August 17, 2009 07:15 CET

US FDA approves Extavia® - the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease
Extavia is branded version of interferon beta-1b, a standard-of-care for multiple sclerosis in the US for more than 16 years[1]
MS affects around 400,000 people in US[2] - one of the most common neurological disorders in young adults[3]
FDA approval marks important step forward for Novartis, laying foundation for innovative approach to treatment of MS
Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has approved Extavia® (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)[4].
The same medicinal product as Betaseron®*, Extavia offers patients and physicians a new branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for MS in the US for more than 16 years[1]. Extavia will be marketed by the Pharmaceuticals Division of Novartis.
"Interferon is a mainstay of treatment in MS," said Doug Jeffery, MD, Associate Professor at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, USA. "With the approval of Extavia, patients have another option with a well-established safety and efficacy profile to help manage this disease."
MS is estimated to affect approximately 400,000 patients in the US[2], of whom more than 80% have relapsing-remitting MS[5]. MS is one of the most common causes of neurological disability in young adults. It is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain[6]. The destruction of myelin causes problems with muscle control and strength, vision, balance, sensation and mental function[7].
"Novartis has been a leader in neuroscience for more than 50 years, having pioneered a number of breakthrough therapies which remain important treatments to this day," said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division. "We are committed to providing new approaches to MS care, and the FDA approval of Extavia marks the beginning of our long-term commitment to the MS community in the US."
Extavia will be available to patients in the US this fall. Along with their prescription for Extavia, patients will be given access to a support program including a nurse helpline, one-on-one injection training and reimbursement support services. Extavia patients will have an autoinjector available to them from Novartis.
"MS is unpredictable and can be difficult to manage," said Aaron Miller, MD, Professor of Neurology at Mount Sinai School of Medicine in New York, USA. "Support programs are an essential element to help patients and physicians effectively manage this complicated disease."
MS typically presents in relapsing forms involving acute self-limiting attacks of neurological dysfunction (known as exacerbations or relapses), followed by complete or partial restoration of function[6].
Interferon beta-1b has been shown to reduce annualized relapse rates by 34% (p=0.0001)[8], with patients nearly twice as likely to remain relapse-free for more than two years compared to those receiving placebo (31% vs. 16%, p=0.007)[8]. In addition, treatment with interferon beta-1b may slow disease progression[9]. After two years, almost three-quarters of patients who experienced a single episode of neurological disease lasting 24 hours or more did not progress to clinically definite MS[10].
In the European Union Extavia is available in 12 countries and is approved for relapsing-remitting MS as well as early MS (defined as a single demyelinating event with an active inflammatory process) and a steadily worsening form of the disease known as secondary progressive MS with relapses.
* Novartis gained the rights to seek approval for its own branded version of interferon beta-1b through agreements with Bayer Schering, the company that markets Betaseron.
Betaseron is marketed under the name of Betaferon® outside the US. Betaseron and Betaferon are registered trademarks of Bayer Schering Pharma AG.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "may," "committed," "long-term commitment," "will," "can," "likely," or similar expressions, or by express or implied discussions regarding potential future multiple sclerosis products or regarding potential future revenues from Extavia or other multiple sclerosis products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional Novartis multiple sclerosis products will be approved for sale in any market. Nor can there be any guarantee that Extavia or such other products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

[Lulu54]

yes, it is the same drug.  Just marketed under a different name by a different company.  You are good with either one!  - Lu

[Guitar_grrrl]

Extavia may be cheaper for the NHS than Betaseron.  Just my $0.02.  Any formulary will go for the cheaper alternative.

[Mand125]

Lulu - Thank you, that is what I hoped was the case.

Guitar_grrrl - Yes that is my thought as well.

Mand

[Sparkysarah]

Hi Mand

I can understand your irritation, but hope that apart from having to get used to a different auto-injector and delivery company that you will feel no change in yourself. If you have found a drug that works and you have no side effects that is fantastic and I do remember being told that it is the same as Betaseron. Obviously all down to cost and it is good to be cynical sometimes. I am not convinced drs always have patients interests at heart when they are managing budgets.

Keep well and let us know when you start and how you get on.

Love Sarah x